MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)

NCT00533312 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

407

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia

Interventions

DRUG: Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks
DRUG: MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks
DRUG: Comparator : niacin / Duraton of Treatment: 4 Weeks

Sponsor

Merck Sharp & Dohme LLC